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The Cannabinoid Content of Legal 
Cannabis in Washington State 
Varies Systematically Across 
Testing Facilities and Popular 
Consumer Products
Nick Jikomes1 & Michael Zoorob2
The majority of adults in the U.S. now have state-legal access to medical or recreational cannabis 
products, despite their federal prohibition. Given the wide array of pharmacologically active compounds 
in these products, it is essential that their biochemical profile is measured and reported to consumers, 
which requires accurate laboratory testing. However, no universal standards for laboratory testing 
protocols currently exist, and there is controversy as to whether all reported results are legitimate. 
To investigate these concerns, we analyzed a publicly available seed-to-sale traceability dataset from 
Washington state containing measurements of the cannabinoid content of legal cannabis products 
from state-certified laboratories. Consistent with previous work, we found that commercial Cannabis 
strains fall into three broad chemotypes defined by the THC:CBD ratio. Moreover, we documented 
systematic differences in the cannabinoid content reported by different laboratories, relative stability 
in cannabinoid levels of commercial flower and concentrates over time, and differences between 
popular commercial strains. Importantly, interlab differences in cannabinoid reporting persisted even 
after controlling for plausible confounds. Our results underscore the need for standardized laboratory 
methodologies in the legal cannabis industry and provide a framework for quantitatively assessing 
laboratory quality.
For millennia, Cannabis has been cultivated for medicinal, recreational, and industrial purposes1. Despite mount-
ing evidence for the legitimate medical utility of cannabis products and their principal psychoactive constitu-
ents2,3, they remain classified as Schedule I controlled substances by the U.S. federal government. Nonetheless, 
public opinion on legal cannabis has changed dramatically in recent years4 and a majority of U.S. states now allow 
legal access to medical cannabis for approved patients, with several states also allowing recreational adult-use5,6. 
This dynamic legal landscape has given rise to a rapidly growing legal cannabis industry that offers a wide variety 
of products to consumers.
Because the core product of this burgeoning industry contains multiple compounds with psychoactive 
and medicinal properties7, it is imperative that the major biochemical constituents of cannabis are accurately 
quantified, and the results made accessible to consumers. Because recreational cannabis products may differ 
substantially from cannabis grown for federally-sanctioned research8 or found on the black market9, there is a 
particular need to study the commercial cannabis being consumed today by millions of adults in states allowing 
legal adult-use consumption.
The adoption of universal industry testing standards will be crucial for comparing data across the many exist-
ing testing laboratories. However, standardized procedures have yet to be adopted, and controversy exists about 
whether all laboratories are accurately measuring and reporting cannabinoid content10. Most of these labs were 
not established quality control labs with a track record of testing food or pharmaceutical products, but rather 
started specifically to focus on cannabis products. At present, there is limited published data8 on the content of 
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commercial cannabis products in the U.S., including quantification of potential differences in the measurements 
reported across these testing laboratories. Reliable testing data will also shed light on questions important to 
consumers and regulators, such as whether cannabinoid levels are changing over time or differ systematically 
between commercial products.
To investigate these concerns, we analyzed a large dataset from Washington state’s seed-to-sale traceability sys-
tem. This dataset comprises hundreds of thousands of measurements of the principal cannabinoids in commercial 
cannabis, including tetrahydrocannabinol (THC) and cannabidiol (CBD). These measurements are available for 
commercial products tested across all state-licensed laboratories since 2014, which allowed us to assess the can-
nabinoid composition of commercial products between laboratories, over time, and across strains.
Results
The Basic Chemotype Landscape of Commercial Cannabis. Cannabis likely evolved in Central Asia, 
and landraces native to regions including Afghanistan, Pakistan, India and China11 have been found to fall into 
three general chemotypes based on genetically-constrained THC:CBD ratios12,13. Consistent with previous work 
in landraces and commercial Dutch Cannabis13,14, we found that commercial Cannabis grown in Washington 
also conforms to this pattern (Fig. 1a–c). Unlike landraces, which are more likely fall into chemotype III (CBD-
dominant) category and generally display lower overall levels of total THC13, most commercial Cannabis falls 
into the chemotype I category, characterized by relatively high total THC and low total CBD levels (Fig. 1d–f; see 
Methods for definition of total THC and CBD levels). While studying the chemotype landscape of these com-
mercial samples, we observed striking differences in THC:CBD distributions across laboratories for both flower 
(Fig. 1d–f, Figure S1) and concentrates (Figure S2). This prompted us to examine interlab differences in more 
detail. In particular, we wished to assess whether this variation stemmed from intrinsic (e.g. methodological) 
differences between laboratories or from heterogeneity in the products submitted to those labs.
THC and CBD Measurements Vary Widely Across Testing Laboratories. To compare cannabinoid 
measurements across labs, we looked at distributions of total THC and CBD levels for the six largest laboratories 
by data volume for different chemotypes and product categories. These labs, referred to henceforth as labs A-F, 
are Confidence Analytics (Lab A), Analytical 360 (Lab B), Green Grower Labs (Lab C), Integrity Labs (Lab D), 
Testing Technologies (Lab E), and Peak Analytics (Lab F). We observed differences in reported values of both 
THC and CBD (Fig. 2). For example, the median total THC content for chemotype I flower products ranged 
from 17.7% to 23.2% between the labs reporting the lowest and highest THC levels, respectively (Fig. 2a; labs A-F 
ordered from lowest to highest median reported THC levels). Pairwise differences in mean THC content between 
labs were statistically significant (p < 0.001 for each pairwise comparison in Fig. 2a, two-sided t-test). To quantify 
the magnitude of differences between labs, we calculated the effect sizes of pairwise differences using two metrics: 
Cohen’s d, the standardized difference between two means15, and a “Common Language” (CL) effect size, the 
probability that a random value from one sample will be greater than a random value from the other16 (Fig. 2b; 
see Analytical Methods).
Calculating effect sizes allows a more intuitive assessment of the magnitude of interlab differences, espe-
cially when very large sample sizes allow even trivial differences between means to reach statistical significance. 
For example, mean THC levels of chemotype I flower for Lab B and Lab A were 18.4% and 17.7%, respectively 
(Fig. 2a and b). While this difference was highly significant due to the large sample sizes, the effect size was small 
(d = 0.13; see Methods). The common language effect size (CL) for this comparison was 0.54, indicating a 54% 
chance that a random THC measurement from Lab B will be larger than a random measurement from Lab A. 
In contrast, when comparing Lab F to Lab A, which reported the highest mean THC levels, the effect size was 
considerably larger (d = 1.28, CL = 0.82).
We observed a similar pattern when comparing CBD measurements across labs for chemotype II and III 
flower samples (Fig. 2c and d) and THC levels for concentrates (Fig. 2e and f). The labs reporting the highest lev-
els of THC for chemotype I flower products also reported the highest levels of CBD for other flower chemotypes 
and THC levels for concentrates (Fig. 2), indicating a systematic tendency for certain labs to report higher levels 
of cannabinoids across chemotypes and product categories. This may be explained by differences in laboratory 
protocols. While most labs report using High Performance Liquid Chromatography (HPLC) to detect cannabi-
noids, the details of each protocol likely differ. Alternatively, interlab differences may be driven by labs receiving 
distinct sets of cannabis products for testing.
Interlab Differences Persist After Controlling for Plausible Confounds. To investigate potential 
determinants of interlab differences, we quantified the average cannabinoid levels reported by each lab after 
accounting for strain name, the producer-processor submitting samples for testing, and time of measurement 
(see Methods). Four separate regression models were estimated: (1) THC levels in chemotype I flower products 
(n = 161,933); (2) THC levels in chemotype I concentrate products (n = 33,888); (3) CBD levels in chemotype II 
and III flower products (n = 4,661); and (4) CBD levels in chemotype II and III concentrate products (n = 2,156). 
Large interlab variability in reported THC and CBD levels persisted across product categories after controlling for 
these factors (Fig. 3). Differences were observed for both flower (Fig. 3a,c) and concentrates (Fig. 3b,d). For chem-
otype I flower, the average adjusted total THC level for Peak Analytics (~23%) was significantly higher (p < 0.001; 
Wald test) than all other labs (Fig. 3a).
For chemotype I concentrates, Lab F’s average reported total THC (~75%) exceeded all other labs, including 
the lab reporting the second-highest average total THC (Lab E, ~70%). For total CBD levels in chemotype II and 
chemotype III flower, Lab F again reported the largest mean quantity, at about 13%, significantly higher (p < 0.01) 
than all other labs (Fig. 3c). For chemotype II and chemotype III concentrates, Lab F’s average products reported 
the highest CBD, but these estimates were uncertain due to the relatively small sample size (Fig. 3d). Overall, 
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these results suggest that the observed differences between laboratories cannot be explained by differences in the 
producers, product types, or strain names of the samples being processed by each lab.
Low-level cannabinoid measurements vary widely across laboratories. Examination of THC:CBD 
distributions across laboratories indicated substantial variation in their propensity to report chemotype I strains 
with low total CBD levels (Figure S1, far right bins). To investigate this further, we plotted the density of chem-
otype I flower products with less than 1% CBD by dry weight (Fig. 4). The shape of these distributions varied 
somewhat across labs, likely due to methodological differences determining their Limit of Quantification (LOQ). 
Similar to what we observed in the THC:CBD histograms (Fig. 1b), these density plots indicate that differences 
exist between labs’ propensity to detect low-levels of CBD in chemotype I flower; they tend to display local max-
ima near 0.1%, which is the LOQ most labs report for cannabinoids.
Figure 1. The THC:CBD ratio defines three broad chemotypes of commercial cannabis flower measured by 
testing labs in Washington. Left column: Scatterplots of total THC vs. total CBD levels for cannabis flower. Right 
column: Histograms showing the THC:CBD ratio on a log scale and indicating the proportion of flower samples 
for each chemotype. Data are displayed for measurements batched across all Labs A-F (panels a-b; n = 175,136), 
for the lab reporting the lowest mean total THC levels (Lab A; panels c-d; n = 62,719), and the lab reporting the 
highest mean total THC levels (Lab F; panels e-f; n=26,664). Histograms for each of the six labs contributing to 
batched data in panels a-b are shown in Figure S1. Panels a and c were subsampled to n=50,000 for visualization 
purposes.
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To further quantify these differences, we compared the proportion of chemotype I flower having <0.1% total 
CBD across laboratories. There were dramatic differences between labs (Fig. 4b), with some reporting substan-
tially more chemotype I flower with total CBD <0.1% than others. The volume of data caused even tiny interlab 
differences to reach high levels of statistical significance (p < 0.001 for all pairwise comparisons, except Lab E vs. 
Lab F, Mann-Whitney U test). Thus, we quantified the effect size of these differences by computing Cohen’s h for 
all pairwise comparisons (Fig. 4c; see Analytic Methods). Many of these interlab differences were of very large 
effect size (|h| >0.80, and often much greater), confirming that there are substantial differences in labs’ propen-
sity to detect low levels of CBD in chemotype I flower. The analyses so far indicate that cannabinoid inflation and 
differences in the ability of labs to detect low-level cannabinoids both contribute to systematic differences in their 
reported measurements.
Figure 2. Total THC and CBD Measurements Differ Between Labs Across Chemotypes and Product 
Categories. Left column: Violin plots showing the distribution of total THC or CBD levels across labs A-F. 
Black lines denote median values, which are printed below the x-axis for each lab. Right column: Effect size 
matrices displaying the effect size of pairwise differences in distributions between labs. Matrices are color-coded 
according to one measure of effect size (Cohen’s d), and a second measure (Common Language) is printed for 
each comparison.
www.nature.com/scientificreports/
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Changes in THC Content of Commercial Cannabis Products Over Time. While modern commercial 
strains contain higher THC levels than recreational cannabis from past decades17,18, it is unclear whether THC 
levels have continued climbing since Washington permitted adult-use cannabis. Thus, we looked for potential 
changes in the total THC content of commercial products in recent years. Because our previous analyses revealed 
systematic interlab variability in cannabinoid measurements, we sought to minimize the potential confound of 
lab-specific “cannabinoid inflation”. Thus, we quantified cannabinoid levels over time, separately for different 
subsets of laboratories: the three labs reporting the lowest mean THC levels (low THC reporting, LTR), the three 
reporting the highest mean THC levels (high THC reporting, HTR), as well as data pooled across laboratories. 
Figure 5a shows mean THC levels, averaged across labs, for chemotype I flower products from June 2014 through 
May 2017. While there was an upward trend from 2014 to early 2015, mean THC levels appear to have largely 
plateaued, with modest fluctuations since 2015 (Fig. 5a). This trend was evident in the pooled data as well as in 
LTR and HTR labs, although HTR labs showed a steeper increase in total THC levels from 2014 to 2015.
To further quantify changes in THC levels over time, we compared total THC levels for each year of data 
(Fig. 5b and c). Median THC levels for chemotype I flower rose from 2014 to 2015 but changed only slightly 
between 2015 and 2017. This was true whether we looked at the three LTR labs (Fig. 5b and c) or the three HTR 
labs (Fig. 5d and e). Again, large sample sizes allowed small differences in mean THC levels to reach statistical 
significance for all pairwise comparisons (p < 0.001, Mann-Whitney U test), except 2015 to 2016 for the HTR 
cohort (p = 0.334, Fig. 5d). After 2014, the effect sizes for year-to-year comparisons were small (Fig. 5b; |Cohen’s 
d| <0.23 for each comparison). Thus, we conclude that there has not been a substantial increase in the THC con-
tent of Washington state’s commercial cannabis flower from since 2015, although there were notable differences 
between LTR and HTR labs. For example, THC distributions from HTR labs were much more skewed (Fig. 5d; 
skew = −0.2) than for low-LTR labs (Fig. 5b; skew = 0.06). In addition, the increase in mean THC values from 
2014 to 2015 was much larger for HTR than LTR labs (4.5% vs. 2.3%, respectively).
We were also interested in whether concentrates have increased in THC levels since 2014, as these products 
contain a much higher THC concentration. Mean THC levels across labs appeared to be relatively flat from 
2014 to 2017 (Figure S3A). There was a small increase in THC levels from 2014 to 2015 for both cohorts of labs 
(Figure S3), although this was smaller than the increase observed for flower. From 2015 onward, there was a small 
decrease in mean THC levels for LTR and HTR labs (Figure S3). Thus, we conclude that, since 2015, there has not 
been a substantial increase in mean THC levels for commercial flower and concentrate products in Washington.
THC Content Across Popular Commercial Categories: Indica, Sativa, and Hybrid. The vernacular 
among cannabis users involves a triad of “indica,” “sativa”, and “hybrid” strains19,20. Recreational consumers and 
popular educational resources often attribute distinctive psychoactive effects to indica and sativa strains21, while 
Figure 3. THC and CBD Levels Vary Between Labs After Controlling for Plausible Confounds. Average 
predicted values (+/− 99% confidence intervals) are shown, by lab, for (a) THC levels in chemotype I flower 
products (n = 161,933); (b) THC levels in chemotype I concentrate products (n = 33,888); (c) CBD levels in 
chemotype II and III flower products (n = 4,661); and (d) CBD levels in chemotype II and III concentrate 
products (n = 2,156) after adjusting for grower, strain-name, and time of measurement. Predicted values were 
generated from fixed-effects regressions with cluster-robust standard errors (see Methods).
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scholars tend to be more skeptical of these claims20,22. In landraces, accessions from indica strains have been 
associated with more THC than sativas13 but indica and sativa recreational products sold in the Netherlands had 
similar THC content14. The term “strain,” although widely used, is not a botanically-accepted term for distin-
guishing plant varieties, and many scholars prefer the term “chemovar” in order to emphasize biochemical differ-
ences between specific Cannabis varieties23 (see Discussion). To investigate potential differences in cannabinoid 
content among commercial strain categories used by consumers, we looked at the distribution of THC content 
of indica, sativa, and hybrid flower samples in Washington’s commercial market. We matched test results using 
their producer-given strain name from the I-502 dataset to the Leafly.com strain database to retrieve their popular 
indica, sativa, or hybrid categorization (see Methods). This matching process yielded 166,594 flower results for 
analysis: 42,711 indica (25.6%), 31,822 sativa (19.1%), and 92,061 hybrid (55.3%) products. While hybrids had 
higher mean levels of THC compared to indicas and sativas, the distributions of THC content among indicas, 
sativas, and hybrids overlapped considerably (Fig. 6a–d).
Figure 4. Labs differ in the propensity to detect low levels of CBD in chemotype I flower. (a) Kernel density 
plots of each lab’s distribution of total CBD levels below 1.0% dry weight for chemotype I flower (y-axis scaled to 
one). Most labs show a local maximum near 0.1% total CBD, which is a commonly reported LOQ. (b) Fraction 
of chemotype I flower with total CBD levels below 0.1% dry weight. Bars indicate proportions +/− 95% CI for 
a binomial proportion. (c) Effect size matrix indicating the magnitude of interlab differences shown in panel B. 
Effect size is quantified as Cohen’s h (see Methods).
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To further quantify differences in THC content, we estimated a bivariate regression model of THC on strain 
category across all labs. The model indicates that hybrid strains have modestly greater THC content, on average, 
than either indica or sativa strains (Fig. 6e; hybrid vs indica: 1.22%, p < 0.001; hybrid vs sativa: 0.89%, p < 0.01). 
The difference in THC between sativa and indica could not be distinguished from sampling variability (sativa vs 
indica: 0.33%, p = 0.230). Moreover, the indica, sativa, hybrid distinction explained only a tiny fraction of THC 
variability between flower samples (r² = 0.016), and the differences in mean THC content had modest effect sizes 
(Hybrid vs Sativa: Cohen’s d = 0.283; Hybrid vs Indica: Cohen’s d = 0.206; Indica vs Sativa: Cohen’s d = −0.079). 
An analogous test for variability in CBD content across strain categories among chemotype 2 and chemotype 3 
flower yielded similar results (Fig. 6f; hybrid vs indica: 2.17%, p < 0.01; hybrid vs sativa: 0.90%, p = 0.261; sativa 
Figure 5. Mean THC Levels for Chemotype I Flower Products Over Time. (a) Total THC levels over time 
averaged across all labs or those reporting the highest or lowest mean THC levels. (b) Distribution of THC 
levels for each year on record for low THC reporting (LTR) labs. (c) Effect size matrix quantifying the mean 
difference in THC levels across years for LTR labs. (d) Distribution of THC levels for each year for high THC 
reporting (HTR) labs, and (e) the effect size matrix quantifying the magnitude of yearly differences.
www.nature.com/scientificreports/
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vs indica: 1.26%, p < 0.05) with modest effect sizes (Hybrid vs Indica: Cohen’s d = 0.148, Hybrid vs Sativa: Cohen’s 
d = 0.068, Sativa vs Indica: Cohen’s d = 0.268).
Importantly, the above results are sensitive to laboratory measurements. Data from most labs reflect the gen-
eral pattern of hybrids having somewhat higher THC than indica and sativa, which are very similar. However, 
performing the same regression solely using flower products from Lab F (n = 22,049), which reports the highest 
mean THC levels, would not detect the higher average THC levels of hybrid flowers (hybrid vs indica: 0.47%, 
p = 0.21; hybrid vs sativa: 0.28%, p = 0.425). Repeating the analysis with solely flower products from Lab A 
(n = 50,610), the lab reporting the lowest mean THC levels, replicates the overall result, with hybrids having 
slightly higher THC than indica (1.13%, p < 0.001) and sativa (0.80%, p < 0.01).
Cannabinoid Variation Within and Across Popular Commercial Strain Names. While commer-
cial flower products fall into one of three chemotypes based on their THC:CBD ratio (Fig. 1), we wondered how 
much THC:CBD ratios varied within and between the popular commercial strain names that flower samples 
are given. Because the strain names of flower products submitted for laboratory testing are simply given by the 
producer-processor, they do not guarantee the true identity of the strain. In fact, personal correspondence with 
industry professionals indicated that we should expect flower samples submitted for testing to be mislabeled to 
some extent, perhaps due to business motives driving products to be given certain strain names based purely on 
their popularity and hence potential market value.
To visualize differences between samples based on their popular commercial strain names, we plotted 
the THC:CBD ratio for 23 labeled strains (fifteen Chemotype I strains, three Chemotype II strains, and five 
Chemotype III strains) based on their consumer popularity (determined by cumulative pageviews on Leafly.
com; see Methods) using data from the labs reporting the lowest (Fig. 7a; Lab A) and highest (Fig. 7b; Lab F) 
mean levels of THC across all flower products. This revealed clear differences in the THC:CBD profiles reported 
by each lab, as well as differences between the THC:CBD ratios of samples labeled with different strain names. 
Moreover, multi-modal distributions were apparent for many strains, with peaks sometimes at drastically dif-
ferent THC:CBD ratios. For example, “Charlotte’s Web” is a popular chemotype III strain that was specifically 
bred to have high total CBD and low total THC levels. Figure 7a clearly shows that many Charlotte’s Web flower 
samples tested in Washington commonly fit this profile, but many also fit the profile of chemotype II and even 
chemotype I products with high total THC levels. Thus, for subsequent analyses, we quantified data before and 
Figure 6. Total THC and CBD Levels Across Popular Consumer Strain Categories for Flower Products. (a) 
Distribution of THC levels across popular strain categories for chemotype I flower and (b) effect size matrix 
quantifying the magnitude of differences between them. (c) Distribution of CBD levels across the same 
categories for chemotype II and III flower and (d) effect size matrix quantifying the magnitude of differences 
between them.
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after filtering by modal chemotype. For example, for a strain name like Charlotte’s Web, this would mean consid-
ering only measurements within the chemotype III cutoffs (see Methods).
To formalize how well colloquial strain names capture variation in THC:CBD profiles, we estimated a series of 
multilevel models with random intercepts for each strain24 to estimate the share of the total variation in the logged 
THC:CBD ratio explained by the strain name, before and after filtering by modal chemotype. This information 
is contained in the Intraclass Correlation Coefficient (ICC), a measure of similarity within-groups calculated as 
the ratio of the within-strain variance to the total variance (see Methods). The ICC is bounded by 0 and 1, where 
a value of 0 indicates that a sample’s strain name is completely uninformative of its THC:CBD ratio and a value of 
1 indicates that a product’s strain name is perfectly predictive of its THC:CBD ratio. In these data, calculating the 
ICC is complicated by the relatively large number of test results with reported zero CBD (and thus an unbounded 
THC:CBD ratio). Thus, ICCs pre-and-post filtering are shown both after omitting results with 0 CBD and coerc-
ing these results to tail values (Fig. 8a; see Methods). When using tail values, results with zero reported CBD were 
coerced to a ratio of 3.5 and results with zero THC coerced to −2.0. These values correspond approximately to the 
most extreme values observed in the data (see Fig. 1b).
Across all labs, the pre-filtered strain ICC was 0.57 (omitting results with zero reported CBD or THC) or 0.41 
(coercing results with zero reported CBD to 3.5 and zero THC to −2.0). After filtering, the ICCs increase, respec-
tively, to about 0.71 and 0.51. This overall test conceals significant variation between labs. Figure 8a shows the 
ICCs with 99% Confidence Intervals, by lab, before and after strain name filtering, separately for the two methods 
of handling results with reported zero CBD. In general, a large portion of the variation in THC:CBD ratio was 
attributable to strain name. This quantity varied substantially between labs, and filtering results outside a strain’s 
modal chemotype typically boosted the proportion of variation explained by strain by between about 0.10 and 
0.15, depending on the model. In all but one case—Lab F, with missing CBD results coerced to a ratio of 3.5—fil-
tering resulted in a statistically significant (p < 0.01, z test) increase in the proportion of variation explained by 
strain. Labs varied substantially in the proportion of zero CBD test results, and, consequently, the ICC was more 
sensitive to the handling of missing data for those labs. For Lab F, the lab with the highest proportion of zero CBD 
results, the ICC was very sensitive to the handling of missing data; the ICC was 0.76 and 0.48, respectively, before 
filtering, and 0.92 and 0.53, after filtering. In contrast, Lab A, which had few zero CBD values, had a stable ICC 
across both methods, with pre-filtered ICCs of 0.65 and 0.64, respectively, and post-filtering ICCs of 0.79 and 
0.78.
Figure 7. Distribution of THC-to-CBD Ratios Vary Across Popular Commercial Strain Names and Between 
Labs. THC-to-CBD ratios plotted on a logarithmic scale for cannabis flower samples across twenty-three 
popular commercial strain names for the single lab (Lab A) reporting the lowest (a) and the single lab (Lab F) 
reporting the highest (b) overall THC levels for cannabis flower.
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Given these observations, we compared total THC and CBD levels across strains only after filtering data by 
laboratory and modal chemotype. Using data from only one laboratory ensured that the same laboratory testing 
protocol was used to measure cannabinoids across flower samples. We chose to use data from Lab A, which 
had the largest number of flower samples. Comparing mean THC or CBD levels revealed clear and statistically 
significant differences (p < 0.01, Wald Test) between many strain names, even within chemotypes (Fig. 8). These 
results suggest that strain names can provide meaningful, though variable, signals of the composition of flower 
samples. Filtering results to the strain’s modal chemotype boosted the proportion of variation explained by strain 
Figure 8. Popular Strain Names as Signal for THC and CBD Content. (a) Proportion of variation in log10 
THC:CBD ratio explained by popular strain names (Intraclass Correlation Coefficient). 99% CIs are shown, by 
lab, before (black circles) and after (gray squares) filtering test results by the modal chemotype of each strain 
name. The ICC is shown both for dropping values for which 0% CBD or 0% THC is reported (left) and coercing 
cannabinoid ratios for these tests (see Methods). (b) Mean THC level of popular chemotype I strains. 99% 
CIs are shown after filtering by modal chemotype, for the lab reporting the lowest THC levels. (c) Mean CBD 
levels for popular chemotype II (above dotted line) and chemotype III (below dotted line) strain names. Results 
shown for the lab reporting the lowest mean THC levels.
www.nature.com/scientificreports/
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clustering by about 0.15. Furthermore, the strength of this signal varies between labs, particularly with respect to 
the CBD content of high-THC flower.
Discussion
Our results confirm that commercial cannabis strains in Washington fall into three principal chemotypes defined 
by their THC:CBD ratio, similar to landrace13 and commercial Dutch strains14. While this result is unsurprising 
given the biological constraints on cannabinoid production25,26, we were able to use this dataset to investigate out-
standing questions about commercial cannabis products widely used by consumers today. These included formal 
analysis of discrepancies in the cannabinoid levels reported by different laboratories, trends in THC content over 
time, and systematic differences in the THC:CBD profiles between flower samples with different labeled strain 
names.
A key area of concern for legal cannabis consumers, industry professionals, and state regulators is the accuracy 
of the state-mandated testing data that is required to be displayed on product packaging. Recent media reports of 
“THC inflation” and high-profile suspensions of state-licensed testing facilities have prompted concern over the 
accuracy of the cannabinoid content of legal cannabis products27. Our analyses revealed clear, systematic differ-
ences in the results obtained by different testing facilities in Washington, with some labs consistently reporting 
higher or lower levels of cannabinoids than others. Moreover, these differences could not be explained by differ-
ences in the producer or strain name associated with the samples being submitted, suggesting that discrepancies 
between labs are likely caused by systematic differences in their testing methodologies. It is crucial that precise 
standards are adopted by the industry to ensure that laboratories produce results that are reproducible across 
labs, independent of the exact testing method used, with the ultimate goal of reporting results that consumers 
can trust. Our analyses provide a potential framework for quantitatively evaluating laboratory quality, including 
labs’ sensitivity to detecting low-level cannabinoids (Fig. 4), agreement with independent measurements of can-
nabis products in scholarly journals (discussed below), and differences between labs after accounting for other 
characteristics.
In our analyses of Washington labs, median THC levels for chemotype I flower varied considerably (Fig. 2), 
ranging from 17.7% to 23.2%. The results reported by labs with lower median THC levels are in better agree-
ment with independent measurements of cannabis flower from legal markets8,28,29. For example, Vergara et al. 
(2017) reported total THC levels for commercial flower samples in several U.S. cities, finding that flower samples 
averaged approximately 19% total THC in Seattle, WA, with even lower levels (~15%) reported for Denver, CO, 
Sacramento, CA, and Oakland, CA8. Other measurements of flower samples originating from medical cannabis 
patients in California found median total THC levels for chemotype I samples to be approximately 17% dry 
weight28. Another study measured THCA across a variety of popular cultivars and found mean THCA levels to 
be just over 16% dry weight for specimens with a broad-leaflet phenotype vs. 14% for those with a narrow leaflet 
phenotype (total THC levels were not reported)29.
Reliable cannabis laboratory testing is an attainable goal. In the absence of federal regulations in the United 
States for the foreseeable future, it will be incumbent on state regulators to implement universal testing stand-
ards for cannabis laboratories. But states have extensive experience in this arena, regulating laboratories that 
analyze drinking water and evidence from crime scenes. They need only hold cannabis laboratories to similar 
standards. A first step may be to require that cannabis labs, like other testing facilities, receive third-party accred-
itation of compliance with International Organization for Standardization (ISO) 17025 guidelines for testing 
and calibration laboratories by auditors who are themselves ISO-accredited30. Second, states could require that 
cannabis labs adhere to a standardized testing protocol for analyzing cannabis to ensure consistency between 
labs. Such protocols have already been developed. For example, the American Herbal Pharmacopoeia published 
a 64-page monograph called Cannabis Inflorescence detailing analytical procedures for cannabinoid detection 
and quantification to establish benchmark methods31. The American Herbal Products Association’s points read-
ers to Cannabis Inflorescence for guidance regarding “specific analytical methods” in its recommendations for 
regulators32. Finally, states should implement regular “round-robin” audits, sending a blinded, common sample 
for testing across various laboratories.
Overall, our results are consistent with reports of “cannabinoid inflation” by certain laboratories10 and point 
to intrinsic characteristics of labs as driving the observed variability, rather than confounds introduced from 
different producers, product types, or strain names being processed by each lab. Previous analysis of data from 
Washington’s traceability dataset found a statistically significant relationship between the price per gram of flower 
and both total THC and total CBD levels33, which may provide an economic incentive for cannabis producers to 
seek test results with higher total THC or CBD levels.
Restricted to the lab reporting the lowest THC levels for chemotype I flower (median = 17.7%), the 99th 
percentile THC level is 27.0%, compared to 31.8% for the lab reporting the highest THC levels. This suggests that 
flower samples with total THC levels approaching or exceeding 30% are very rare, and that many flower products 
labeled as containing >30% total THC by dry weight may be inaccurate. Our analysis of changes in THC content 
over time suggest that THC levels have not risen substantially, at least since 2015 (Fig. 5). While it is well-known 
that modern recreational cannabis contains higher levels of THC than it did in previous decades17, this appar-
ent plateauing in recent years may be expected due to biological limits imposed on cannabinoid production. In 
Cannabis, total potential THC levels are determined by levels of THCA synthesized within the plant, which is 
under genetic control26,34.
In general, our results do not suggest that flower samples labeled as indica, sativa, and hybrid differ substan-
tially in terms of total THC content or THC:CBD profiles, as the indica/sativa/hybrid typology accounted for only 
about 1% of the relative variability in THC content (r² = 0.016). Samples labeled sativa vs. indica in Washington’s 
commercial market do not differ in THC content, similar to what was documented among commercial strains in 
the Netherlands14. However, we did find that hybrid strains have slightly higher levels of total THC. Since hybrid 
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strains are produced by crossing indica and sativa varieties, this result is somewhat counterintuitive. We inter-
pret it as potentially owing to the selective breeding of hybrid strains to maximize THC content for commercial 
purposes. It is also possible that, on average, these group are grown under different growing conditions, such as 
indoors vs. outdoors.
While there were no substantial differences in the THC or CBD content between flower samples labeled as 
indica vs. sativa, our analyses were limited by the contents of the Washington traceability dataset, which did not 
include measurements of other phytocannabinoids or terpenes, a major class of aromatic compounds produced 
by Cannabis that likely modulate the effects of phytocannabinoids7,23,25,35. It remains possible that indica and 
sativa samples differ systematically in their full phytocannabinoid or terpene profile. Indeed, a recent analysis of 
cannabinoid and terpene profiles from Dutch flower samples found several terpenes that may serve as markers for 
indica- vs. sativa-type samples14. Other recent work23 has shown how more complete sets of biochemical meas-
urements, including terpenoid profiles, can be used to define multiple distinct Cannabis chemovars.
Since flower samples with different strain names within each of the three principal chemotypes can be dif-
ferentiated somewhat by their THC:CBD ratio, more detailed analysis of the biochemical composition of com-
mercial strains may uncover further differences. Indeed, previous work has attempted to differentiate strains 
based on analysis of more complete cannabinoid and terpene profiles14,28,36,37 in an effort to define Cannabis 
“chemovars”23,38. An important area of future research will be to define the chemovars for commercially available 
cannabis products in legal U.S. markets. Applying computational approaches to large-scale cannabinoid and ter-
pene datasets will allow cannabis strains and products to be organized according to their biochemical constituents 
rather than colloquial strain names. Accurate data quantifying the principal constituents of cannabis could foster 
the development of “product maps” that organize commercial products based on levels of their psychoactive and 
medically-relevant compounds. However, doing so requires having accurate lab testing data in the first place, 
which requires the establishment of laboratory testing standards that ensure the correct identification and quan-
tification of the contents of cannabis products. Our results highlight the need for such standards given the large, 
systematic differences observed between laboratories in Washington.
Methods
Data. Washington I-502 Cannabis Test Data. We submitted public records requests for all test results regis-
tered with the Washington State Liquor and Cannabis Board (LCB), the agency which regulates cannabis sales. 
The request was made on August 7, 2017 and the LCB provided us the raw data files on August 14, 2017. These 
data contained cannabinoid profiles, grower and laboratory information, and test date for 304,123 test results 
from June 2014 through May 2017 (excluding a very small number of test results that were dropped from the 
dataset for containing mathematically or biologically impossible values, such as THC content greater than 100%). 
The data files from which we extracted data for our analyses are attached online.
We focused our analyses on two product categories: flower and concentrates. “Flower” refers to products refer 
to those comprised of the mature female flower of the cannabis plant, which most cannabis products are derived 
from. Our analyses of flower products came from data in the “Flower Lot” group, which can be found in the 
InventoryLabel column of the I-502 dataset accompanying this paper. Our analyses of concentrate products refer 
to data with the “Hydrocarbon Wax” InventoryLabel, which was the largest single group for product types that 
would normally be considered concentrates. We did not explore data from other product categories in this study, 
including “Hash,” “Marijuana Infused Edibles,” and a variety of others. We encourage other scholars to mine this 
dataset for further insights.
Calculation of THC and CBD Levels. Cannabis plants do not synthesize THC or CBD; instead, they synthesize 
the cannabinoid acids THCA and CBDA, which are made from a common precursor12 and must be decarbox-
ylated (e.g. by heat energy) to yield the phytocannabinoids THC and CBD. Thus, cannabis products, especially 
flower samples, contain mainly THCA and/or CBDA, as well as small levels of THC and CBD that result from 
spontaneous decarboxylation during the cultivation process. Total THC or CBD levels, in units of percent of dry 
weight, are typically calculated as:
= . × +Total CBD CBDA CBD(0 877 ) (1)
= . × +Total THC THCA THC(0 877 ) (2)
Where THCA and THC refer to the percent dry weight concentration of each cannabinoid present in a cannabis 
product, and 0.877 is the scaling factor accounting for the difference in molecular weight between THCA and 
THC. “Total THC” or “Total CBD” refers to this value, which is the maximum potential THC or CBD content of 
a cannabis product, assuming 100% decarboxylation of cannabinoid acids. This is the standard way of reporting 
“total” cannabinoid levels for legal cannabis products in Washington. Unless otherwise noted, “THC levels” or 
“total THC levels” refers to this value (similar for CBD levels).
Leafly data. Leafly’s database of strains was used to group test results, as described in the matching process 
below. The Indica, Sativa, or Hybrid categorization from Leafly.com allowed us to categorize strains according to 
their popular consumer designations. Our data matched to 1,318 unique commercial strains. The popularity of 
consumer strain names were determined by cumulative pageviews of the strain pages on Leafly.com.
Analytic Methods. Matching Strain Names. Strain names in the Washington I-502 seed-to-sale traceabil-
ity data were matched to a database of Leafly strains to retrieve information about strain popularity and indica/
sativa categorization. The matching process had two stages. First, I-502 data strain names were standardized 
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using regular expressions to delete reference to grower’s names and cities, correct spelling irregularities, and 
expand acronyms (e.g. “GDP” referring to the strain “Granddaddy Purple”). Second, the processed I-502 strain 
names were matched to the Leafly database using open-source implementations of two different Approximate 
String Matching algorithms (Ratcliff/Obershelp and Levenshtein Distance). If the two algorithms agreed, then 
the test result was assigned the Leafly strain. Through this process, used to minimize the number of false positive 
matches, 214,747 (70.6%) results were matched to Leafly strains, including 166,594 for flower samples and the 
remainder for other product types. A complete list of raw strain names and their corresponding Leafly match can 
be found in the Supplementary Information files.
Chemotype Cutoffs. Following previous scholars13, test results were classified into chemotypes based on the dis-
tinct groups visible after plotting the log10 THC-to-CBD ratio. For our analyses, we defined chemotype I strains as 
any with a 5:1 THC:CBD ratio or greater, chemotype III strains as any with a 1:5 THC:CBD ratio or lower, and the 
remainder of products were classified as Chemotype II. We called the “strain chemotype” the modal chemotype 
among test results of that strain (in the matched Leafly data).
Statistical Significance and Effect Size for Very Large Samples. Due to the size of the I-502 dataset we analyzed, 
statistical comparisons often involved samples with tens of thousands of data points each, and statistically signif-
icant results were often achieved even for trivial differences between sample means with highly overlapping dis-
tributions. Thus, we calculated effect size in a variety of ways to determine whether differences between samples 
were relatively large or small. When comparing continuous distributions, we computed effect size in two ways: 
Cohen’s d15,39 and a “Common Language” (CL) effect size metric16.
The CL effect size measures the probability that a randomly selected value from one population will be greater 
than a randomly selected value from another while Cohen’s d measures effect size as the difference between two 
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where y denotes each sample mean, and n and s2 are the size and variance of each sample, respectively.
For example, Fig. 2a shows that Lab A (Confidence Analytics) and Lab B (Analytical 360) report slightly 
different median THC values for flower (17.6% and 18.3%, respectively) and display highly overlapping dis-
tributions. Performing a t-test to measure a difference in the means (17.5% and 18.0%, respectively) returns 
p-value < 1.1 × 10−52. While the t-test indicates a statistically significant result, |Cohen’s d| = 0.13, indicating a 
“small effect”15. Similarly, the CL effect size is 0.46, indicating that a random value from Confidence Analytics will 
be greater than a random value from Analytical 360 46% of the time, which is close to what identical distributions 
would display (50%). The effect size matrices displayed in this paper allow one to assess whether differences 
between samples are relatively large or small, which is especially useful when large sample sizes allow small dif-
ferences to reach statistical significance.
For comparing different proportions, we computed Cohen’s h15, which is the difference between two propor-
tions’ arcsine transformation:
= −h arcsin p arcsin p2 2 (4)i j
Cannabinoid Inflation Regression Models. Each of the four regression models shown employed a fixed-effect 
transformation for each grower-strain combination to absorb heterogeneity in cannabinoid content attributable 
to these factors40. Written in the Least Squares Dummy Variable formulation, each equation takes the form:
∑ ∑β δ γ η= + + +
= =








where y denotes the cannabinoid content of a particular test t from lab l of producer-strain s, S indexes each 
producer-strain combination (omitting one), and L indexes each lab (omitting one); D’s are indicator variables 
denoting group (lab and strain) membership, and η is the idiosyncratic model error. The primary quantity of 
interest is γ, the expected deviation in cannabinoid content for each lab relative to the omitted lab, adjusting for 
grower/strain and test date. As a robustness check, for regressions subsetted to concentrate products, an addi-
tional dummy variable for type of concentrate (e.g. “Bubble Hash”, “Butane Hash Oil”, “CO2 Hash Oil”) was 
included to control for potential heterogeneity between labs in their stock of concentrate products, since con-
centrates differ in potency by their production method41; inclusion of this variable does not materially alter the 
results. Standard errors were clustered by grower-strain, since the number of clusters is large (there were 22,716 
grower-strain combinations) and residuals are likely to be correlated within clusters42. Average covariate-adjusted 
cannabinoid values across labs are plotted with 99% Confidence Intervals estimated through the delta-method 
using Stata’s margins command, holding covariates at their actual values43.
THC and CBD Variation Across Popular Commercial Strains. To examine clustering in THC:CBD ratio by strain 
name, we estimated unconditional two-level hierarchical models with random intercepts for each strain, across 
all labs and separately by lab. Each specification took the following form:
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γ μ ε= + +r (6)ts s ts
(2)
where r is the THC:CBD ratio for each test t of strain s, γ is the “global-mean” THC:CBD ratio across all strain 
names, μ is the level-two random intercept for each strain (capturing the variance of the mean for each strain 
around the overall mean), and ε is the deviation of each test from its strain mean. The Intraclass Correlation 
Coefficient (ICC) is calculated as the ratio of the within-group variance to the total variance, which can be 
decomposed into the within-group variance and the between group variance. Here, the ICC ρ is the ratio of the 














which is strictly bounded between 0 (when there is zero within-strain variance) and 1 (when there is zero 
between-strain variance). The random intercept models were estimated using Stata’s mixed command; the 
post-estimation command estat icc, l(99) was used to calculate 99% Confidence Intervals with a logit transforma-
tion to accommodate the restricted domain of the ICC and the delta method to estimate standard errors.
Strain Category Cannabinoid Estimation. Regression was used to estimate whether indica, sativa, and hybrid 
flower products differed systematically in THC and CBD. Standard errors were clustered by strain, since indica, 
sativa, hybrid is a strain-level property. There were 1,318 unique strains.
Data Availability Statement. All data generated or analyzed during this study are included in this published 
article (and its Supplementary Information files). They are also available in the Harvard Data Repository (https://
doi.org/10.7910/DVN/E8TQSD).
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